Hereditary persistence of fetal hemoglobin is a condition in which levels of HbF persist at levels greater than usual.

The switch from fetal γ-globin to adult β-globin is controlled by BCL11A. Genetic manipulation of BCL11A improves disease outcomes by turning γ-globin expression back on to compensate for ...

Some people with sickle cell disease have milder symptoms due to fetal hemoglobin persistence.

FLT1 is among 14 new genetic markers of fetal hemoglobin the scientists identified from GWAS data gathered and used with permission from 3,751 people with sickle cell disease.

BEAM-101 aims to potentially alleviate the effects of mutations causing SCD by leading to increases in fetal hemoglobin (HbF), which inhibits hemoglobin S (HbS) polymerization.

Those people have what is called hereditary persistence of fetal hemoglobin, something that all infants have, though most people’s blood switches over to adult hemoglobin at around 6 months old.

--Beam Therapeutics Inc., a biotechnology company developing precision genetic medicines through base editing, today announced the company will encore data from the BEACON Phase 1/ 2 clinical ...

Those people have what is called hereditary persistence of fetal hemoglobin, something that all infants have, though most people’s blood switches over to adult hemoglobin at around 6 months old.

At five months post-treatment, the first patient treated with EDIT-301 has a total hemoglobin of 16.4 g/dL, a fetal hemoglobin (or HbF) of 45.4%, and a mean corpuscular HbF of 13.8 pg/red blood ...

Hydroxycarbamide acts by turning on a gene that leads to the production of fetal hemoglobin, which is not affected by the sickle cell disease mutation.

Updated data from 17 patients treated with BEAM-101 demonstrated robust and durable increases in fetal hemoglobin (HbF) and reductions in sickle hemoglobin (HbS), rapid neutrophil and platelet ...